Early neuropsychiatric symptoms may represent preclinical Alzheimer’s disease. Elevated amyloid beta levels and the worsening of anxiety symptoms may be linked.
- Higher amyloid beta burden is associated with increasing anxious-depressive symptoms.
- Amyloid beta levels are crucially involved in Alzheimer’s disease.
- Emerging neuropsychiatric symptoms represent an early manifestation of preclinical Alzheimer’s disease.
Past studies have suggested depression and other neuropsychiatric symptoms may be predictors of Alzheimer's disease’s progression during its "preclinical" phase, during which time brain deposits of fibrillar amyloid and pathological tau accumulate in a patient's brain.
Anxiety, risk factor for Alzheimer's disease
"Rather than just looking at depression as a total score, we looked at specific symptoms such as anxiety. When compared to other symptoms of depression such as sadness or loss of interest, anxiety symptoms increased over time in those with higher amyloid beta levels in the brain," said first author Nancy Donovan, MD, a geriatric psychiatrist at Brigham and Women's Hospital. "This suggests that anxiety symptoms could be a manifestation of Alzheimer's disease prior to the onset of cognitive impairment. If further research substantiates anxiety as an early indicator, it would be important for not only identifying people early on with the disease, but also, treating it and potentially slowing or preventing the disease process early on."
Higher brain amyloid beta burden is associated with increasing anxiety symptoms
As anxiety is common in older people, rising anxiety symptoms may prove to be most useful as a risk marker in older adults with other genetic, biological or clinical indicators of high AD risk.
Researchers derived data from the Harvard Aging Brain Study, an observational study of older adult volunteers aimed at defining neurobiological and clinical changes in early Alzheimer's disease. The participants included 270 community dwelling, cognitively normal men and women, between 62 and 90 years old, with no active psychiatric disorders. Individuals also underwent baseline imaging scans commonly used in studies of Alzheimer's disease, and annual assessments with the 30-item Geriatric Depression Scale (GDS), an assessment used to detect depression in older adults.
The team calculated total GDS scores as well as scores for three clusters symptoms of depression: apathy-anhedonia, dysphoria, and anxiety. These scores were looked at over a span of five years.
Donovan notes further longitudinal follow-up is needed to determine whether these escalating depressive symptoms give rise to clinical depression and dementia stages of Alzheimer's disease over time.
- Nancy J. Donovan, Joseph J. Locascio et al. Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults, American Journal of Psychiatryhttps://doi.org/10.1176/appi.ajp.2017.17040442
Source-Eurekalert